Impaired Noradrenaline Homeostasis in Rats with Painful Diabetic Neuropathy as a Target of Duloxetine Analgesia
Open Access
- 1 January 2013
- journal article
- research article
- Published by SAGE Publications in Molecular Pain
- Vol. 9, 59
Abstract
Background: Painful diabetic neuropathy (PDN) is a serious complication of diabetes mellitus that affects a large number of patients in many countries. The molecular mechanisms underlying the exaggerated nociception in PDN have not been established. Recently, duloxetine (DLX), a serotonin and noradrenaline re-uptake inhibitor, has been recommended as one of the first-line treatments of PDN in the United States Food and Drug Administration, the European Medicines Agency and the Japanese Guideline for the Pharmacologic Management of Neuropathic pain. Because selective serotonin re-uptake inhibitors show limited analgesic effects in PDN, we examined whether the potent analgesic effect of DLX contributes toward improving the pathologically aberrant noradrenaline homeostasis in diabetic models.Results: In streptozotocin (STZ) (50 mg/kg, i.v.)-induced diabetic rats that exhibited robust mechanical allodynia and thermal hyperalgesia, DLX (10 mg/kg, i.p.) significantly and markedly increased the nociceptive threshold. The analgesic effect of DLX was nullified by the prior administration of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) (50 mg/kg, i.p.), which drastically eliminated dopamine-beta-hydroxylase- and norepinephrine transporterimmunopositive fibers in the lumbar spinal dorsal horn and significantly reduced the noradrenaline content in the lumbar spinal cord. The treatment with DSP-4 alone markedly lowered the nociceptive threshold in vehicle-treated non-diabetic rats; however, this pro-nociceptive effect was occluded in STZ-treated diabetic rats. Furthermore, STZ-treated rats exhibited a higher amount of dopamine-beta-hydroxylase- and norepinephrine transporterimmunopositive fibers in the dorsal horn and noradrenaline content in the spinal cord compared to vehicle-treated rats.Conclusions: Impaired noradrenaline-mediated regulation of the spinal nociceptive network might underlie exaggerated nociception in PDN. DLX might exert its analgesic effect by selective enhancement of noradrenergic signals, thus counteracting this situation.Keywords
This publication has 71 references indexed in Scilit:
- Insulin resistance in the nervous systemTrends in Endocrinology & Metabolism, 2012
- Increased Presynaptic and Postsynaptic α2-Adrenoceptor Activity in the Spinal Dorsal Horn in Painful Diabetic NeuropathyThe Journal of Pharmacology and Experimental Therapeutics, 2011
- A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathyBritish Journal of Pharmacology, 2011
- Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: prediction for efficacy in animal models of neuropathic pain?British Journal of Pharmacology, 2011
- A greater role for the norepinephrine transporter than the serotonin transporter in murine nociceptionNeuroscience, 2011
- Mechanisms Underlying Purinergic P2X3 Receptor-Mediated Mechanical Allodynia Induced in Diabetic RatsMolecular Pain, 2011
- Streptozotocin-Induced Early Thermal Hyperalgesia is Independent of Glycemic State of Rats: Role of Transient Receptor Potential Vanilloid 1(TRPV1) and Inflammatory MediatorsMolecular Pain, 2011
- Insulin Reveals Akt Signaling as a Novel Regulator of Norepinephrine Transporter Trafficking and Norepinephrine HomeostasisJournal of Neuroscience, 2010
- Brain derived nerve growth factor induces spinal noradrenergic fiber sprouting and enhances clonidine analgesia following nerve injury in ratsPain, 2008
- Noradrenergic agonist administration into the central nucleus of the amygdala increases the tail-flick latency in lightly anesthetized ratsNeuroscience, 2007